{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T21:45:30Z","timestamp":1775943930291,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe \u00dcniversitesi","doi-asserted-by":"publisher","award":["THD-2016-12638"],"award-info":[{"award-number":["THD-2016-12638"]}],"id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plefa.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.plefa.2023.102590","type":"journal-article","created":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:06:48Z","timestamp":1694866008000},"page":"102590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Decreased plasma levels of sphingolipids and total cholesterol in adult cystic fibrosis patients"],"prefix":"10.1016","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-0452","authenticated-orcid":false,"given":"Dilara","family":"Bal Topcu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berrin","family":"Er","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutay","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutfi","family":"Coplu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Incilay","family":"Lay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9744","authenticated-orcid":false,"given":"Yesim","family":"Oztas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.plefa.2023.102590_bib0001","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijmm.2010.08.011","article-title":"Cftr-dependent susceptibility of the cystic fibrosis-host to pseudomonas aeruginosa","volume":"300","author":"Grassme","year":"2010","journal-title":"Int. J. Med. Microbiol."},{"issue":"1","key":"10.1016\/j.plefa.2023.102590_bib0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1165\/rcmb.2007-0036OC","article-title":"Fenretinide corrects newly found ceramide deficiency in cystic fibrosis","volume":"38","author":"Guilbault","year":"2008","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0003","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm1748","article-title":"Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis","volume":"14","author":"Teichgraber","year":"2008","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1164\/rccm.200905-0799OC","article-title":"Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease","volume":"182","author":"Brodlie","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jcf.2010.03.001","article-title":"Alveolar inflammation in cystic fibrosis","volume":"9","author":"Ulrich","year":"2010","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"6","key":"10.1016\/j.plefa.2023.102590_bib0006","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1165\/rcmb.2009-0174OC","article-title":"Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis","volume":"42","author":"Becker","year":"2010","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"9","key":"10.1016\/j.plefa.2023.102590_bib0007","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00109-012-0867-2","article-title":"Role of cd95 in pulmonary inflammation and infection in cystic fibrosis","volume":"90","author":"Becker","year":"2012","journal-title":"J. Mol. Med."},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0008","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbrc.2013.03.032","article-title":"Ceramide mediates lung fibrosis in cystic fibrosis","volume":"434","author":"Ziobro","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.plefa.2023.102590_bib0009","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.intimp.2006.06.012","article-title":"Inhibition of il-8 release from cftr-deficient lung epithelial cells following pre-treatment with fenretinide","volume":"6","author":"Vilela","year":"2006","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jcf.2007.09.001","article-title":"Fenretinide prevents the development of osteoporosis in cftr-ko mice","volume":"7","author":"Saeed","year":"2008","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"1","key":"10.1016\/j.plefa.2023.102590_bib0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1165\/rcmb.2008-0279OC","article-title":"Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide","volume":"41","author":"Guilbault","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0012","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1165\/rcmb.2008-0264OC","article-title":"Cftr regulation of intracellular ph and ceramides is required for lung endothelial cell apoptosis","volume":"41","author":"Noe","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1165\/rcmb.2008-0295OC","article-title":"Defective acid sphingomyelinase pathway with pseudomonas aeruginosa infection in cystic fibrosis","volume":"41","author":"Yu","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0014","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/lipd.12230","article-title":"Plasma ceramides and sphingomyelins of pediatric patients increase in primary ciliary dyskinesia but decrease in cystic fibrosis","volume":"55","author":"Bal Topcu","year":"2020","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.plefa.2023.102590_bib0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","article-title":"Chain length-specific properties of ceramides","volume":"51","author":"Gr\u00f6sch","year":"2012","journal-title":"Prog. Lipid Res."},{"issue":"Suppl 2","key":"10.1016\/j.plefa.2023.102590_bib0016","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S1569-1993(11)60009-X","article-title":"New clinical diagnostic procedures for cystic fibrosis in europe","volume":"10","author":"De Boeck","year":"2011","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"Suppl 2","key":"10.1016\/j.plefa.2023.102590_bib0017","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(11)60012-X","article-title":"Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the eurocarecf working group on outcome parameters in clinical trials","volume":"10","author":"Bilton","year":"2011","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0018","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/lipd.12027","article-title":"Decreased serum levels of sphingomyelins and ceramides in sickle cell disease patients","volume":"53","author":"Aslan","year":"2018","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.plefa.2023.102590_bib0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbrc.2013.03.032","article-title":"Ceramide mediates lung fibrosis in cystic fibrosis","volume":"434","author":"Regan","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.plefa.2023.102590_bib0021","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jcf.2020.01.010","article-title":"Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis","volume":"19","author":"Horati","year":"2020","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"10","key":"10.1016\/j.plefa.2023.102590_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000672","article-title":"Genetic determinants of circulating sphingolipid concentrations in european populations","volume":"5","author":"Hicks","year":"2009","journal-title":"PLoS Genet."},{"issue":"11","key":"10.1016\/j.plefa.2023.102590_bib0023","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1194\/jlr.M009449","article-title":"Lipidomics reveals a remarkable diversity of lipids in human plasma","volume":"51","author":"Quehenberger","year":"2010","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.plefa.2023.102590_bib0024","doi-asserted-by":"crossref","first-page":"e62968","DOI":"10.1371\/journal.pone.0062968","article-title":"Ceramide synthases expression and role of ceramide synthase-2 in the lung: insight from human lung cells and mouse models","volume":"8","author":"Petrache","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.plefa.2023.102590_bib0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00408-020-00353-2","article-title":"Age-dependent progression in lung pathophysiology can be prevented by restoring fatty acid and ceramide imbalance in cystic fibrosis","volume":"198","author":"Youssef","year":"2020","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0026","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1159\/000373964","article-title":"Plasma phosphatidylcholine alterations in cystic fibrosis patients: impaired metabolism and correlation with lung function and inflammation","volume":"35","author":"Grothe","year":"2015","journal-title":"Cell. Physiol. Biochem. Int. J. Experim. Cell. Physiol. Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0027","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00394-020-02358-2","article-title":"Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, pemt and intestinal microbiota","volume":"60","author":"Bernhard","year":"2021","journal-title":"Eur. J. Nutr."},{"issue":"10","key":"10.1016\/j.plefa.2023.102590_bib0028","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00109-017-1564-y","article-title":"Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating cers5 enzyme: evidence from bench to bedside","volume":"95","author":"Gari\u0107","year":"2017","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.plefa.2023.102590_bib0029","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.plipres.2019.03.001","article-title":"Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: the importance of side chain","volume":"74","author":"Gari\u0107","year":"2019","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"10.1016\/j.plefa.2023.102590_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jcf.2022.02.005","article-title":"Cftr modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis","volume":"21","author":"Westh\u00f6lter","year":"2022","journal-title":"J. Cystic Fibrosis Offic. J. Eur. Cystic Fibrosis Soc."},{"issue":"6","key":"10.1016\/j.plefa.2023.102590_bib0031","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","article-title":"Abnormal lipid concentrations in cystic fibrosis","volume":"75","author":"Figueroa","year":"2002","journal-title":"Am. J. Clin. Nutr."},{"issue":"4330","key":"10.1016\/j.plefa.2023.102590_bib0032","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1126\/science.203033","article-title":"Serum lipoprotein concentrations in cystic fibrosis","volume":"199","author":"Vaughan","year":"1978","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.plefa.2023.102590_bib0033","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cmet.2017.12.003","article-title":"Could ceramides become the new cholesterol?","volume":"27","author":"Summers","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.plefa.2023.102590_bib0034","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12944-018-0948-5","article-title":"Untargeted mass spectrometry lipidomics identifies correlation between serum sphingomyelins and plasma cholesterol","volume":"18","author":"Zalloua","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.plefa.2023.102590_bib0035","article-title":"Coronary artery disease in patients with cystic fibrosis - a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.plefa.2023.102590_bib0036","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvac169","article-title":"Ceramide risk scores can bring lipidomics to clinical medicine","author":"Ramos","year":"2022","journal-title":"Clin. Chem."},{"key":"10.1016\/j.plefa.2023.102590_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/clinchem\/hvac158","article-title":"Ceramides and phosphatidylcholines associate with cardiovascular diseases in the elderly","author":"Katajam\u00e4ki","year":"2022","journal-title":"Clin. Chem."}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327823000595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327823000595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:12:47Z","timestamp":1760602367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327823000595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"alternative-id":["S0952327823000595"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102590","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased plasma levels of sphingolipids and total cholesterol in adult cystic fibrosis patients","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2023.102590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102590"}}